# Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine

## TL;DR

This study examines how a combination of Novavax and Pfizer vaccines affects the body's ability to neutralize different SARS-CoV-2 Omicron subvariants.

## Contribution

The study introduces a novel vaccine regimen combining NVX-CoV2373 and BNT162b2 and evaluates its neutralization efficacy against Omicron subvariants.

## Key findings

- A durable neutralizing antibody response was observed against Omicron BA.4/BA.5 and BA.1 at six months post-booster.
- Immune escape was noted for the XBB.1.5 variant following the vaccine regimen.

## Abstract

We evaluated the immunologic response to a novel vaccine regimen that included 2 doses of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent booster vaccine. A durable neutralizing antibody response to Omicron BA.4/BA.5 and BA.1 variants was observed at month 6 after the booster, while immune escape was noted for the XBB.1.5 variant.